Originally published as JCO Early Release 10.1200/JCO.2005.05.5335 on September 11 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nemunaitis, J. Articles by Fakhrai, H. Search for Related Content PubMed PubMed Citation Articles by Nemunaitis, J. Articles by Fakhrai, H.

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

John Nemunaitis, Robert O. Dillman, Paul O. Schwarzenberger, Neil Senzer, Casey Cunningham, Jodi Cutler, Alex Tong, Padmasini Kumar, Beena Pappen, Cody Hamilton, Edward DeVol, Phillip B. Maples, Lily Liu, Terry Chamberlin, Daniel L. Shawler, Habib Fakhrai

From the Mary Crowley Medical Research Center/Texas Oncology Professional Association; Baylor Sammons Cancer Center, Baylor University Medical Center; Murex Pharmaceutical Inc; Institute for Health Care Research and Improvement, Baylor Health Care System, Dallas, TX; Hoag Cancer Center, Newport Beach; NovaRx Corporation, San Diego, CA; and Louisiana State University, New Orleans, LA

Address reprint requests to John Nemunaitis, MD, 1717 Main St, 60th Floor, Dallas, TX 75201; e-mail: jnemunaitis{at}mcmrc.com

PURPOSE: Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that demonstrates enhancement of tumor antigen recognition as a result of transforming growth factor beta-2 inhibition.

PATIENTS AND METHODS: We performed a randomized, dose-variable, phase II trial involving stages II, IIIA, IIIB, and IV non–small-cell lung cancer patients. Each patient received one of three doses (1.25, 2.5, or 5.0 x 10⁷ cells/injection) of belagenpumatucel-L on a monthly or every other month schedule to a maximum of 16 injections. Immune function, safety, and anticancer activity were monitored.

RESULTS: Seventy-five patients (two stage II, 12 stage IIIA, 15 stage IIIB, and 46 stage IV patients) received a total of 550 vaccinations. No significant adverse events were observed. A dose-related survival difference was demonstrated in patients who received 2.5 x 10⁷ cells/injection (P = .0069). Focusing on the 61 late-stage (IIIB and IV) assessable patients, a 15% partial response rate was achieved. The estimated probabilities of surviving 1 and 2 years were 68% and 52%, respectively for the higher dose groups combined and 39% and 20%, respectively, for the low-dose group. Immune function was explored in the 61 advanced-stage (IIIB and IV) patients. Increased cytokine production (at week 12 compared with patients with progressive disease) was observed among clinical responders (interferon gamma, P = .006; interleukin [IL] -6, P = .004; IL-4, P = .007), who also displayed an elevated antibody-mediated response to vaccine HLAs (P = .014). Furthermore, positive enzyme-linked immunospot reactions to belagenpumatucel-L showed a correlation trend (P = .086) with clinical responsiveness in patients achieving stable disease or better.

CONCLUSION: Belagenpumatucel-L is well tolerated, and the survival advantage justifies further phase III evaluation.

published online ahead of print at www.jco.org on September 11, 2006.

Supported in part by Small Business Innovative Research Grant No. 1 R44 CA96025 (H.F.).

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				G. Wallraven, J. J. Nemunaitis, and P. B. Maples Compassionate Approval Process for Experimental Gene-Based Products J. Clin. Oncol., April 10, 2008; 26(11): 1899 - 1900. [Full Text] [PDF]

				J. J. Nemunaitis Are Vaccines Making a Comeback in Non-Small-Cell Lung Cancer? J. Clin. Oncol., March 20, 2008; 26(9): 1402 - 1403. [Full Text] [PDF]

				E. N. Vinageras, A. de la Torre, M. O. Rodriguez, M. C. Ferrer, I. Bravo, M. M. del Pino, D. A. Abreu, S. A. Brooks, R. Rives, C. del Castillo Carrillo, et al. Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., March 20, 2008; 26(9): 1452 - 1458. [Abstract] [Full Text] [PDF]

				Y. Shintani, M. Maeda, N. Chaika, K. R. Johnson, and M. J. Wheelock Collagen I Promotes Epithelial-to-Mesenchymal Transition in Lung Cancer Cells via Transforming Growth Factor Signaling Am. J. Respir. Cell Mol. Biol., January 1, 2008; 38(1): 95 - 104. [Abstract] [Full Text] [PDF]

				S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270. [Abstract] [Full Text] [PDF]